How Frequently Is Asthma Objectively Demonstrated before Starting a Biologic? Quality Assessment of a Group Practice of Allergists and Immunologists

Worldwide, asthma-related healthcare cost remains a major burden. Individuals with severe asthma account for 50% of that cost. Although they are expensive, biologics such as anti-IL5 and anti-IgE agents promise cost-effectiveness when judiciously used to decrease asthma-related hospitalization and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Dziewa, Iwona, Craig, Timothy, Al-Shaikhly, Taha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766929/
https://www.ncbi.nlm.nih.gov/pubmed/33352823
http://dx.doi.org/10.3390/ijerph17249482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766929/
https://www.ncbi.nlm.nih.gov/pubmed/33352823
http://dx.doi.org/10.3390/ijerph17249482

Ejemplares similares